Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alnylam Pharmaceuticals is conducting a Phase 3 study titled ‘TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.’ The study aims to assess the effectiveness of nucresiran in reducing mortality and cardiovascular events in patients suffering from this condition, while also evaluating its impact on patients’ health status and quality of life.
The intervention being tested is a drug named nucresiran, administered subcutaneously every six months. It is designed to treat transthyretin amyloidosis with cardiomyopathy by potentially reducing cardiovascular-related mortality and events.
This study is interventional, with participants randomly assigned to receive either nucresiran or a placebo. It employs a parallel intervention model and is quadruple-masked, meaning participants, care providers, investigators, and outcomes assessors are unaware of the assignments. The primary purpose is treatment-focused.
The study began on June 30, 2025, with the primary completion date yet to be announced. The latest update was submitted on August 27, 2025. These dates are crucial as they indicate the study’s progress and potential timeline for results.
For investors, this study could significantly impact Alnylam Pharmaceuticals’ stock performance, especially if nucresiran proves effective. Success in this trial could enhance Alnylam’s market position in treating transthyretin amyloidosis, potentially affecting competitors in the cardiovascular treatment sector.
The study is currently recruiting, and further details can be found on the ClinicalTrials portal.